NCT05953012View on ClinicalTrials.gov

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

October 30, 2025

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

PMC-403

PMC-403 will be administered Intravitreal.

Trial Locations (4)

13620

RECRUITING

Seoul National University Bundang Hospital, Seoul

42415

RECRUITING

Yeungnam University, Daegu

03722

RECRUITING

Yonsei University Health System, Seoul

05505

RECRUITING

ASAN Medical Center, Seoul

Sponsors

Lead Sponsor

PharmAbcine

Collaborators (1)

C&R Research, Inc.
All Listed Sponsors
collaborator

C&R Research, Inc.

INDUSTRY

lead

PharmAbcine

INDUSTRY

NCT05953012 - Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter